PFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999
|
|
- Flora Barber
- 5 years ago
- Views:
Transcription
1 PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Lyrica /pregabalin PROTOCOL NO.: PROTOCOL TITLE: Pregabalin BID Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study in Patients With Partial Seizures (Protocol ) Study Center(s): 71 US centers and 5 centers in Canada Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999 Phase of Development: Phase 3 Study Objective(s): The objectives of this study were to evaluate the efficacy and safety of 4 dosages of pregabalin administered BID as add-on treatment in patients with partial seizures. METHODS Study Design: Following screening and an 8-week baseline period, patients entered a 12- week, randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Randomization was to either placebo, or to 1 of 4 pregabalin dose groups: 50, 150, 300, or 600 mg/day administered BID. Current antiepileptic drug (AED) therapy was maintained. Clinic visits were scheduled on Days -56 and -28 during baseline, Day -1 at randomization, Days 14, 28, 56, and 84 during double-blind, and one follow-up visit during the interval Days Number of Subjects (Planned and Analyzed): Planned: 400 patients randomized, 80 per treatment arm (assuming approximately a 10% loss in primary efficacy population, defined as Evaluable, would provide a minimum of 70 patients per treatment arm to be included in the primary analysis. Analyzed: A total of 455 patients were randomized to treatment: 100 to placebo; 88 to pregabalin 50 mg/day; 88 to pregabalin 150 mg/day; 90 to pregabalin 300 mg/day; and 89 to pregabalin 600 mg/day. Two patients randomized to receive pregabalin 150 mg/day did not take any study medication and were not included in efficacy or safety analyses. Page 1
2 Diagnosis and Main Criteria for Inclusion: Men or nonpregnant, nonlactating women 12 years of age and older, of any race, weighing at least 40 kg (88 lb) with partial seizures (simple partial, complex partial, and/or secondarily generalized tonic clonic) were eligible. Patients were included who failed to have adequate seizure control in the past while on standard AEDs and continued to be receive 1 to 3 standard AEDs at doses within an acceptable therapeutic range. Study Treatment: Capsules; pregabalin 25 mg, pregabalin 100 mg, and matching placebo. Administration: capsules administered twice daily (BID). Duration of treatment: 12 weeks. Efficacy Evaluations: Primary: The primary criterion to establish the efficacy of pregabalin was the reduction in the frequency of all partial seizures during the double-blind period compared with the baseline period. For each patient, the baseline period was defined as Study Days -56 to -1. The double-blind period was defined as starting on Study Day 1 and ending on the day the patient withdrew from or completed the study. The number of days in the treatment period for a given patient could have been less or greater than the 12 weeks planned for in the protocol. The observed seizure rate during baseline and double-blind was standardized for a 28-day period. Patients with no double-blind seizure data had their baseline seizure rate carried forward into the double-blind period in order to include all ITT patients. Because the amount of diary data and duration of time in the double-blind period of the study varied from patient to patient, the 28-day seizure rate was defined as follows: Period in the above formula was either the baseline phase or double-blind phase of the study. Secondary: The secondary efficacy parameters were: Responder rate, which was defined as the percent of patients who had at least a 50% reduction in 28-day frequency of seizures during treatment compared with baseline; and Percent change, which was defined as percent change in 28-day seizure frequency during treatment compared with baseline. Additional secondary parameters assessed by descriptive statistics were: The length of seizure-free intervals and the number of seizure-free days per a 28-day period; and RRatio, responder rate, and percent change for each seizure type. Pharmacokinetic Evaluations: Pharmacokinetic: Standard plasma/serum AED concentration and plasma pregabalin concentrations were assessed periodically during the study. Page 2
3 Safety Evaluations: Safety was evaluated by recording adverse events at each clinic visit; frequency and intensity of adverse events were summarized and evaluated Physical (including vital signs assessments) and neurological examinations were performed at each clinic visit during the study. 12-lead electrocardiogram (ECG) with a 2-minute cardiac rhythm strip were obtained at baseline (Day -56) and during double-blind at Days 14 and 84. Laboratory tests including hematology, blood chemistry, and urinalysis were obtained at baseline (Day -56), at randomization (Day -1), during double-blind (Days 14, 28, 56, and 84) and at follow-up (Days ). Pregnancy testing was performed at each clinic visit during the study. Visual examinations (acuity, funduscopy, and visual fields) were performed baseline (Day -56) and at the termination of double-blind (Day 84); visual-related adverse events were also reviewed. Statistical Methods: The primary efficacy parameter was response ratio (RRatio or symmetrized percent change) as a comparison of baseline 28-day partial seizure rate (B) with treatment 28-day partial seizure rate (T) according to the formula: RRatio = [(T- B)/(T+B)] 100. Analysis was performed using an analysis of variance (ANOVA) model with treatment (as main effect) and center (clusters) and RRatio as the dependent variable (= 0.049, 2-sided). Secondary efficacy parameters were the responder rate, defined as the proportion of patients who had a 50% reduction in seizure rate during treatment as compared to baseline, and the percent change (PCH) in 28-day seizure rates in treatment compared to baseline. The responder rate was compared between treatments using a Cochran-Mantel-Haenszel chisquare analysis stratified by center (clusters). RRatio, responder rate, and percent change were also summarized by seizure type. The length of seizure-free intervals and the number of seizure-free days per a 28-day period planned evaluation) and number and percent of patients who were seizure free (ad hoc analysis) were also assessed. The primary analysis population was the intent-to-treat (ITT) population (all patients randomized who received at least one dose of study medication). The secondary analysis population was the evaluable population (all patients randomized who received at least 28 days of study medication and had a minimum of 28 days of seizure diary data within both the baseline phase and the double-blind phase). Page 3
4 RESULTS Subject Disposition and Demography: Patient disposition, including the number of patients withdrawing during baseline, is summarized in Table 1. Table 1. Summary of Patient Disposition [Number (%) of Patients] A total of 455 patients were randomized to treatment, and 453 received treatment (ITT). Two patients randomized to the 150 mg/day group did not take study medication, Patient changed AEDs during baseline and Patient withdrew consent. Patient characteristics in the randomized population were comparable to those of the patients in the ITT population discussed in the following paragraphs. In general, patient characteristics were similar across the 5 treatment groups for the ITT population (Table 2). Of the 453 patients in the ITT population, 100 were randomized to the placebo group, 88 to the 50 mg/day pregabalin group, 86 to the 150 mg/day pregabalin group, 90 to the 300 mg/day pregabalin group, and 89 to the 600 mg/day pregabalin group. Patients were primarily white (85%) and at screening had a mean age of 38 years (range, 12 through 75 years), with a mean age of 14 years at diagnosis of epilepsy. Page 4
5 Table 2. Summary of Patient Characteristics: ITT Population Efficacy Results: Overview: On the basis of the primary efficacy parameter, RRatio, efficacy was demonstrated at doses of 600, 300, and 150 mg/day of pregabalin. Consistent results were seen with regard to the secondary efficacy parameters. Patients in the 600, 300, and 150 mg/day pregabalin groups had statistically significantly greater responder rates compared to placebo. Pregabalin showed a significant linear response (decrease in RRatio value, increase in responder rate) with increasing dose. Based on the RRatio, all pregabalin treatment groups, except for the 50 mg/day group, showed statistically significantly greater reductions in seizures compared to the placebo group (based on the Ruberg step down procedure for controlling the overall type I error rate at 0.049). The 150 mg/day group was a minimum effective dose. Mean RRatio data are summarized in Figure 1. Page 5
6 Figure 1. Mean Change in All Partial Seizure (RRatio ITT Populaiton) Responder rate: A patient was classified as a responder if they experienced at least a 50% reduction in seizure frequency compared to the baseline. All pregabalin groups, except for the 50 mg/day group, had statistically significantly greater responder rates, compared to placebo. Percent change: The median percent change from baseline for the ITT population was -51% in the 600 mg/day, -37% in the 300 mg/day, -35% in the 150 mg/day, -9% in the 50 mg/day pregabalin groups and 0% in the placebo group. These results support the RRatio results. Results by seizure type: In general, the efficacy endpoint for each seizure type showed similar trends to those seen for all partial seizures combined, with dose-related reductions over the entire double-blind period seen at doses of 600, 300, and 150 mg/day. Pharmacokinetic and Other Results: Pharmacokinetic: Three hundred and eleven patients from this study were included in the pharmacokinetic analysis. A total of 558 plasma samples from patients randomized to pregabalin and considered to be at steady-state (patient continued for at least 48 hours without a missed dose or dosage adjustment) and collected within 18 hours from the last dose taken were included in the analysis. The plasma pregabalin concentrations associated with a daily dose of 50, 150, 300, and 600 mg/day averaged (range) ( ), 1.63 ( ), 2.84 ( ), and 5.47 ( ) ug/ml, respectively. Page 6
7 Safety Results: Overview: The percentage of patients with one or more adverse events was higher for the 600 (89%) and 300 mg/day (84%) pregabalin groups than for the placebo group (74%); with a similar pattern seen for associated adverse events. The percentages of patients in the 150 and 50 mg/day treated groups with adverse events and with associated adverse events in any and all body system(s) were comparable to that of placebo. Table 3. TESS (Treatment Emergent Signs or Symptoms) Adverse Events Occurring in 3% Total Pregabalin Patients By Decreasing Frequency [Number (%) of Patients] The majority of adverse events in the placebo and in all pregabalin groups were mild or moderate in intensity. However, the proportion of patients with moderate or severe adverse events was higher in the 600 mg/day pregabalin group. The severe adverse events were mostly CNS in nature. Table 4 summarizes the withdrawals due to adverse events. Page 7
8 Table 4. Summary of Withdrawals Due to TESS Adverse Events Occurring in 3 Pregabalin Patients [Number (%) of Patients] No deaths occurred during the study. Serious adverse events that occurred in the study are summarized in Table 5. Table 5. Table Summary of Serious Adverse Events (TESS) [Number (%) of Patients] Vision assessments: There is no evidence of a dose-related increase in the frequency of treatment-emergent visual abnormalities in this study. Page 8
9 Pediatric Data: Too few patients were enrolled in the study to derive definitive conclusions regarding efficacy or safety in pediatric patients. Pediatric data for 11 patients between 12 and 16 years of age were available in Study Of the 10 children who received pregabalin, 6 (60.0%) experienced at least 1 adverse event: 2 were randomized to pregabalin 600 mg/day, 2 to 300 mg/day, 1 to150 mg/day, and 1 to 50 mg/day. Five of the 6 children with adverse events had events related to the central nervous system. Fewer children experienced dizziness (1 of 10 patients, 10.0%) compared to the pregabalin-treated patients in the total epilepsy population (219 of 758 patients, 28.9%), and none of the children experienced somnolence. Four children had adverse events related to emotional/behavioral changes (hostility, agitation and personality disorder, agitation, emotional lability); 2 of these children had a history of behavioral problems. One patient withdrew from the study due to hostility; the other 3 patients were maintained on their assigned doses and completed the study. None of the adverse events related to emotional/behavioral changes met the criteria for a serious adverse event and all were mild or moderate in intensity. One child who received placebo did not experience any adverse events. CONCLUSION(S): In patients with partial seizures not adequately controlled with available AEDs: Pregabalin administered BID at doses of 150, 300, and 600 mg/day is highly effective as add-on therapy when compared to placebo, exhibiting a clear dose response in the primary and secondary efficacy parameters. Pregabalin 50 mg/day is a no effect dose, while 150 mg/day is the minimum effective dose. Pregabalin, with no initial titration, is well-tolerated at doses of 50, 150, and 300 mg/day, and is well-tolerated by most patients at 600 mg/day. The pharmacokinetics of pregabalin are dose-proportional and predictable. Page 9
PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationBRL /RSD-101C0F/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationBRL /RSD-101RLL/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationPFIZER INC. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Cerebyx / Fosphenytoin Sodium
PFIZER INC These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Lyrica / Pregabalin
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationPFIZER INC. Study Initiation Date: 15 June 1995; Completion Date: 22 April 1996
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Cerebyx /fosphenytoin
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More information(+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]pyrimidin-4- one
SYNOPSIS Issue Date: 18 November 2008 Document No.: EDMS-PSDB-9006510:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Ortho-McNeil Janssen Scientific Affairs, L.L.C. Paliperidone
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationJanssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag
More informationSponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia
Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A
More informationIRBES_R_04320 Generic drug name: Irbesartan + amlodipine Date: Study Code: 31 active centers: 20 in Korea, 7 in India and 4 in Philippines.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationSynopsis (C0743T09 PHOENIX 2)
Monoclonal antibody () Synopsis ( PHOENIX 2) Protocol: EudraCT No.: 2005-003530-17 Title of the study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More informationPFIZER INC. GENERIC DRUG NAME and/or COMPOUND NUMBER: 5% Spironolactone Cream/ PF
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationThis was a multinational, multicenter study conducted at 14 sites in both the United States (US) and Europe (EU).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. NAME OF SPONSOR/COMPANY: Genzyme Corporation,
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Vfend /Voriconazole
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Lyrica / PROTOCOL
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationNo May 25, Eisai Co., Ltd.
No.16-35 May 25, 2016 Eisai Co., Ltd. EISAI TO LAUNCH IN-HOUSE DEVELOPED ANTIEPILEPTIC DRUG FYCOMPA (PERAMPANEL HYDRATE) AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES IN
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More informationPFIZER INC. PROTOCOL TITLE: Efficacy and Safety of the Authentic Recombinant Human Somatropin Genotropin in Children with Familial Short Stature
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationClinialTrials.gov Identifier: Sponsor/company: sanofi-aventis
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBC
CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : FEXOFENADINE Study number : PJPR0024 Study title : A double-blind, randomized, placebo-controlled, parallel study comparing the efficacy and safety of three dosage strengths of MDL 16,455A
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: ABT-639 Name of Active Ingredient: ABT-639 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEVOFLOXACIN Study number : LOFBO-OTMD-002 Study title : A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More informationChris Rundfeldt 1,4*, Andrea Tipold 2,3 and Wolfgang Löscher 3,4
Rundfeldt et al. BMC Veterinary Research (2015) 11:228 DOI 10.1186/s12917-015-0548-9 RESEARCH ARTICLE Open Access Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationPOPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development
POPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development Definition Population Pharmacokinetics Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/054. (For National Authority Use Only) Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex Sodium Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationResults. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study
Poster 5-20 Effect of Gastric ph on the Bioavailability of in Healthy Subjects James Longstreth, PhD, Marijke H. Adams, PharmD, PhD, 2 Vasi Sperry, PhD, 3 Dan Kajdasz, PhD, 3 Carol R. Reed, MD 3 Longstreth
More informationPhRMA Clinical Study Synopsis Protocol CTN / (A /A ) 21 August 2006 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationA Guide to Your Visits for the FAiRE LGS Study
A Guide to Your Visits for the FAiRE LGS Study ( Fenfluramine Assessment in Rare Epilepsy) Thank you for enrolling in the FAiRE-LGS research study. This study will assess whether an investigational drug
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLondon, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION
London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION 1/15 EMEA 2006 1. Introduction Epilepsy is one of the most common and challenging neurological disorders.
More informationAnne M. Calkins, 1 Joseph Shurman, 2 Mark Jaros, 3 Richard Kim, 4 Gwendoline Shang 4. New York Spine and Wellness Center, North Syracuse, NY; 2
Peripheral Edema and Weight Gain in Adult Patients With Painful Diabetic Peripheral Neuropathy Receiving Gabapentin Enacarbil or Pregabalin Enrolled in a Randomized, Phase 2 Trial Anne M. Calkins, 1 Joseph
More informationPFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A3924 4 November 24 Final PFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. GENERIC DRUG NAME / COMPOUND NUMBER: Tofacitinib / CP-690,550
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Niaspan Name of Active Ingredient: Page: Niacin extended-release
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More information